Annals of Oncology Advance Access published online on October 27, 2006
Annals of Oncology, doi:10.1093/annonc/mdl398
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Switzerland, and European Institute of Oncology, Milan, Italy
* To whom correspondence should be addressed. St Gallen Expert Consensus meetings update evidence on treatment of early breast cancer every 2 years and interpret its significance for treatment of individual patients. Such interpretation is controversial. Clinical decisions cannot, however, be postponed, and the harms of failing to tailor treatment must be balanced against those of overinterpretation. Since the ninth meeting in January 2005, an extraordinary year of progress has significantly changed the landscape in breast cancer therapy. The panel in January recommended a fundamental change in selection of adjuvant systemic therapy, giving prime attention to endocrine responsiveness. Primarily, three categories were acknowledged: endocrine responsive in which the primary treatment should be endocrine, endocrine non-responsive in which endocrine therapy should not be used, and an intermediate group for which both endocrine and other therapies should be offered. Secondarily, three risk groups were defined: low, intermediate, and high, slightly modifying the previous classification. In June 2005, three trials, supported in December by a fourth, demonstrated the additional contribution of targeted therapy with trastuzumab in appropriately selected patients. Reports from several trials strengthened the evidence supporting the inclusion of taxanes, though controversy persists concerning their use in endocrine-responsive disease. This commentary midway between St Gallen meetings, therefore, emphasizes how new information influences algorithms for selecting adjuvant therapy in a rapidly changing environment.
Received September 17, 2006
Accepted September 19, 2006
original article
First--select the target: better choice of adjuvant treatments for breast cancer patients
A. Goldhirsch 1 *, A. S. Coates 2, R. D. Gelber 3, J. H. Glick 4, B. Thürlimann 5, and H.-J. Senn 6, On behalf of the St Gallen Expert Panel Members 
2 FRACP AStat, International Breast Cancer Study Group and University of Sydney, Sydney, Australia
3 Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
4 Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
5 Senology Center of Eastern Switzerland, Kantonsspital, Gallen
6 Zentrum für Tumordiagnostik und Prävention, Silberturm, Grossacker, Rorschacherstrasse Gallen, Switzerland
A. Goldhirsch, E-mail: aron.goldhirsch{at}ibcsg.org
Abstract
Participating investigators and institutions are listed in the ‘Acknowledgements’.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. J. Burstein, I. Souter, H. A. D'Alessandro, and D. C. Sgroi Case 25-2009 -- A 36-Year-Old Woman with Hormone-Receptor-Positive Breast Cancer N. Engl. J. Med., August 13, 2009; 361(7): 699 - 707. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Y. Wonders and B. S. Reigle Trastuzumab and Doxorubicin-Related Cardiotoxicity and the Cardioprotective Role of Exercise Integr Cancer Ther, March 1, 2009; 8(1): 17 - 21. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Schmidt, A. Victor, D. Bratzel, D. Boehm, C. Cotarelo, A. Lebrecht, W. Siggelkow, J. G. Hengstler, A. Elsasser, M. Gehrmann, et al. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial Ann. Onc., February 1, 2009; 20(2): 258 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Harbeck, I. Nimmrich, A. Hartmann, J. S. Ross, T. Cufer, R. Grutzmann, G. Kristiansen, A. Paradiso, O. Hartmann, A. Margossian, et al. Multicenter Study Using Paraffin-Embedded Tumor Tissue Testing PITX2 DNA Methylation As a Marker for Outcome Prediction in Tamoxifen-Treated, Node-Negative Breast Cancer Patients J. Clin. Oncol., November 1, 2008; 26(31): 5036 - 5042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schmidt, D. Hasenclever, M. Schaeffer, D. Boehm, C. Cotarelo, E. Steiner, A. Lebrecht, W. Siggelkow, W. Weikel, I. Schiffer-Petry, et al. Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer Clin. Cancer Res., September 15, 2008; 14(18): 5849 - 5855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Laser, J. Cangiarella, B. Singh, J. Melamed, L. Chiriboga, H. Yee, and F. Darvishian Invasive Lobular Carcinoma of the Breast: Role of Endothelial Lymphatic Marker D2-40 Ann. Clin. Lab. Sci., January 1, 2008; 38(2): 99 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Veneziani, V. Criniti, C. Cavaliere, S. Corvigno, A. Nardone, S. Picarelli, G. Tortora, F. Ciardiello, G. Limite, and S. De Placido In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches Mol. Cancer Ther., December 1, 2007; 6(12): 3091 - 3100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colleoni, N. Rotmensz, P. Maisonneuve, A. Sonzogni, G. Pruneri, C. Casadio, A. Luini, P. Veronesi, M. Intra, V. Galimberti, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer Ann. Onc., October 1, 2007; 18(10): 1632 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann. Onc., July 1, 2007; 18(7): 1133 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nichols The Fight Against Tamoxifen Resistance in Breast Cancer Therapy: A New Target in the Battle? Mol. Interv., February 1, 2007; 7(1): 13 - 16. [Abstract] [Full Text] [PDF]
|
|